Denali Therapeutics Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$419M
D&A
$11M
Operating Income
$-555M
EBITDA
$-544M
Tax Provision
$102K
Net Income
$-513M
Operating Margin
—
Net Margin
—
Deferred Tax Assets
$16M
Deferred Tax Liabilities
$0
DTA Valuation Allowance
$631M
Tax Credit Carryforwards
$155M
NOL Carryforwards
$230M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.3%
ETR Foreign Differential (pp)
0.0%
Operating Lease Cost
$8M
Revenue YoY Variation
-100.0%
Income YoY Variation
-14.0%